<DOC>
	<DOCNO>NCT01931137</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) NNC0123-0000-0338 ( insulin 338 ) tablet formulation three different coating healthy subject .</brief_summary>
	<brief_title>A Trial Investigating Pharmacokinetics Pharmacodynamics NNC0123-0000-0338 Tablet Formulation With Three Different Coatings Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Body mass index 18.028.0 kg/m^2 ( inclusive ) Subject consider generally healthy base medical history , physical examination , result vital sign , ECG ( electrocardiogram ) clinical laboratory test perform screen visit , judge investigator Known suspect hypersensitivity trial product relate product Previous participation trial . Participation define informed consent Presence clinically significant acute gastrointestinal symptom ( e.g . nausea , vomit , heartburn diarrhoea ) within 2 week prior first dose , judge investigator</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>